Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a report published on Wednesday.

Brainstorm Cell Therapeutics Trading Up 0.8 %

Brainstorm Cell Therapeutics stock opened at $1.25 on Wednesday. The business’s 50 day simple moving average is $2.24 and its 200 day simple moving average is $4.54. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.89. The company has a market cap of $7.13 million, a price-to-earnings ratio of -0.26 and a beta of 0.40.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to its most recent filing with the SEC. The fund acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.